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Abstract
Background: Endoscopic submucosal dissection (ESD) has become one of the mainstays of treatment for early
gastric cancer (EGC). Radical surgery is also a classical treatment method for EGC. There have been no systematic
clinical studies of the curative effects and adverse events associated with ESD vs. radical surgery for EGC. This study
investigated the therapeutic efficacy and safety of ESD and radical surgery for EGC.
Methods: Twenty-nine patients with EGC underwent ESD, and 59 underwent radical surgery at Weihai Municipal
Hospital. The pathological characteristics, postoperative outcomes, hospital course, morbidity and mortality were
retrospectively compared between the two groups.
Results: The oncological clearance was 93.1 % (27/29) in the ESD group. Postoperative delayed haemorrhage
occurred in two patients. The hospital stay ranged from 10 to 23 days, and the average stay was 14.3 ± 3.7 days.
The patients were followed-up for 1 to 5 years, with a mean follow-up of 26.9 ± 8.5 months. Regular endoscopic
examinations showed that the wound had healed with no cancer recurrence in all of the patients. In the radical
surgery group, the oncological clearance was 100 % (59/59). The hospital stay ranged from 11 to 55 days, and the
average stay was 21.7 ± 9.3 days. The patients were followed-up for 1 to 3.7 years, with a mean follow-up of 22.3 ±
9.4 months. Nine patients developed complications, including acute postoperative adhesive ileus (1/59) and
symptomatic residual gastritis (3/59). These complications were improved by an additional operation, drainage,
gastrointestinal decompression and comprehensive therapy.
Conclusions: ESD achieved similar efficacy and had many advantages compared with radical surgery for the
treatment of EGC.
Keywords: Endoscopic submucosal dissection, Radical operation, Early gastric cancer
Background
Gastric cancer is one of the most common malignant tu-
mours and is the second leading cause of cancer death
worldwide [1]. In China, the mortality rate of gastric
cancer is the highest of all cancers and accounts for
23.2 % of the total mortality caused by malignancy [2].
Despite advances in the diagnosis and treatment of gas-
tric cancer, the prognosis of this type of tumour remains
poor because the vast majority of patients are diagnosed
at an advanced stage. Therefore, it is necessary to
identify ways to diagnose and treat gastric cancer at an
earlier stage [3].
Surgery is the conventional and most definite loco-
regional treatment for early gastric cancer (EGC) [4].
However, surgery for gastric cancer is associated with
significant perioperative morbidities. Because of postop-
erative anatomical and physiological alterations, some
patients suffer from refractory complications, such as
serious oesophageal acid reflux, bile reflux gastritis,
remnant gastric cancer and difficult defecation [5–9].
Hence, surgery is also associated with a significant de-
crease in the quality of life (QOL) of patients [5–9]. In
recent years, endoscopic submucosal dissection (ESD)
has been advocated as a new approach for EGC
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treatment. It has many advantages, such as its minimally
invasive nature, good curative effect, shorter average
hospitalisation time and the fact that the normal physio-
logical structure of the gastrointestinal tract is retained
[10–13]. Although various complications have been de-
scribed, including bleeding, perforation, stenosis, aspir-
ation pneumonia, phlegmonous gastritis, mediastinal
emphysema, residual tumour or recurrence, the ESD-
related complication rates have been relatively low [14].
However, there have not been any systematic clinical
studies of the curative effects, complications, recurrence
rates, and QOL of patients who underwent ESD com-
pared with those who underwent a radical operation for
the treatment of EGC. Therefore, we conducted a retro-
spective cohort study comparing radical surgery with
ESD for the treatment of EGC.
In recent years, endoscopic submucosal dissection
(ESD) has become widely accepted as a less invasive
treatment for early gastric cancer (EGC) [10–13]. Rad-
ical surgery is the classical treatment for EGC [4].
Twenty-nine patients with EGC underwent ESD and 59
underwent radical surgery for EGC from August 2007 to
March 2012 at Weihai Municipal Hospital. The follow-
up period was at least 1 year for all patients. The patho-
logical characteristics, postoperative outcomes, hospital




We retrospectively reviewed the records of the patients
with EGC who underwent ESD or radical surgery who
were admitted to Weihai Municipal Hospital between
August 2007 and March 2012. The patients admitted
during this period were divided into a conventional rad-
ical surgery group and an ESD group according to the
therapeutic method used. The patient background data,
complete resection (CR) rate, length of the operation,
blood loss, perforation rate, curative effect, long-term
complications, recurrence rate and QOL were compared
between the groups. Patients with severe underlying dis-
ease, such as heart disease, respiratory disease, liver dis-
ease or a bleeding tendency, were excluded from the
indications for both ESD and radical surgery at our insti-
tute; however, no patients had severe underlying disease
in this study. If patients had taken drugs to prevent clot-
ting, such as aspirin or warfarin, the ESD or radical op-
eration was performed after a fixed term of drug
discontinuance.
All patients fulfilled the following criteria: the tumour
was limited to the mucosal or submucosal layers without
distant organ or any lymph node involvement detected
using a combined examination by endoscopic ultrason-
ography (EUS), PET scanning and abdominal computed
tomography (CT); in addition, the diameter of the lesion
was not more than 50 mm. The performance status (PS)
of each patient was less than 2 on the Eastern Coopera-
tive Oncology Group (ECOG) scale. All patients who
underwent ESD or radical resection were discussed at an
MDT meeting (Gastrointestinal Surgery, Gastroenter-
ology, Radiology, Interventional Radiology, and Oncol-
ogy departments). Finally, 29 patients with EGC who
underwent ESD and 59 patients with EGC who under-
went a radical operation from August 2009 to March
2012 at Weihai Municipal Hospital were included in the
study.
After being enrolled, the ESD or radical operation was
performed with the consent of these patients after they
were hospitalised and informed of the risks and benefits
of the treatment methods. Written and informed con-
sent was obtained to publish and to report individual pa-
tient data from all patients, and the study was conducted
upon approval by the Ethics Committee of Weihai
Municipal Hospital. More than 100 ESD procedures had
been performed before starting the study.
Surgical procedures
ESD technique
The margins of the lesion were delineated before ESD
using narrow-band imaging (NBI) and 0.4 % indigo car-
mine dye spraying and were marked with argon plasma
coagulation (APC). The submucosa was raised through
submucosal injection. After the injection, a circumferen-
tial incision was made using a HOOK-knife. Repeated
injections were performed to lift the lesion, and the le-
sion was cut using an IT knife. The ulcer bed after the
en-bloc resection was treated by hot biopsy forceps and
APC. Some wounds were closed with metal clips. All
lesions were sent for a pathological examination.
Technique used for radical surgery
Radical distal gastrectomy with D2 dissection
First, a routine exploration of the abdominal cavity was
performed. The left greater omentum was then dissected
from the transverse colon and the lymph nodes along
the left gastroepiploic vessels (No. 4sb). Then, the right
omentum and the lymph nodes were dissected along the
right gastroepiploic vessels (No. 4d). The superior mes-
enteric vein, Henle's trunk, right colic vein, and right
gastroepiploic vein and artery were exposed to allow for
dissection of lymph nodes No. 6 and 14v. Then, the
suprapyloric nodes (No. 5) and the nodes along the
proper hepatic artery (No. 12a) were dissected, followed
by dissection of the nodes along the left gastric artery
(No. 7) and nodes along the celiac artery (No. 9). Subse-
quently, the nodes along the common hepatic artery
(No. 8a) and the proximal splenic artery (No. 11p) were
dissected. The duodenum was transected just distal to
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the pyloric ring using a 45-mm Endo-GIA stapler. This
was followed by dissection of the lesser curvature in the
remnant stomach, with dissection of the right cardial
nodes (No. 1) and the nodes along the lesser curvature
(No. 3). Subsequently, the stomach on the upper third
above the tumour was transected. Finally, an upper mid-
line incision (approximately 5 cm) was made, the gas-
trectomy was performed and the gastrointestinal
continuity was restored using a Billroth I or II anasto-
mosis through this incision. All lesions were sent for a
pathological examination.
Radical proximal gastrectomy with D2 dissection
The D2 lymphadenectomy was performed in the same
manner as described above. The gastrointestinal con-
tinuity was reconstructed in the oesophagogastric anas-
tomosis through this incision.
Histological assessment
A pathologist evaluated the specimens obtained by ESD
or radical surgery, paying special attention to the depth
of tumour invasion and the lateral and deep margins of
the excision. The resected specimens were cut into 2-
mm slices and evaluated to determine whether cancer-
ous glands were present at the margin of each slice.
Definitions of complete and incomplete resection
When the margins were definitely free of tumorous
glands after the ESD procedure, the resection was con-
sidered to be complete. Multi-fragment resections were
incomplete when tumorous glands were present in one
or more fragments histologically. If the lateral margin of
the lesion could not be evaluated histologically because
of the effects of the electrosurgical current or mechan-
ical damage, the resection was considered incomplete.
The assessment of complete and incomplete resections
after radical surgery was similar to that after ESD. When
the margin of resected specimens, the distal resected
omentum, and the distal lymph nodes were definitely free
of tumorous glands, the resection was considered to be
complete. Resections were defined as incomplete when tu-
morous glands were present in one or more the distal
resected omentum and/or lymph nodes histologically.
Follow-up
The follow-up gastroscopy and observation were per-
formed at 1, 3, 6, and 12 months postoperatively. The
Chinese versions of the European Organization for Re-
search and Treatment of Cancer (EORTC) Quality of
Life Questionnaire Core 30 (QLQ-C30) and a gastric
cancer-specific module, the EORTC QLQ-STO22, were
used to assess the QOL. The scores were calculated by
investigating 15 scales from the EORTC QLQ-C30 and
nine scales from the EORTC QLQ-STO22. In the
EORTC QLQC30, the QOL is higher when the general
health and functional scale scores are higher, and the
QOL is lower when the symptom scale score is higher.
In the EORTC QLQ-STO22, the QOL is lower when the
scores for each category are higher [15–17]. The follow-
up deadline was March 2013. All patients underwent
gastroscopy, and pathological biopsies were collected to
assess the patients for residual or recurrent tumours.
The recent and long-term complications and their man-
agement were investigated. The shortest follow-up
period was 1 year, and the longest was 5 years.
Statistical analysis
The values are expressed as the means ± SD. The statis-
tical analysis was performed using the unpaired Students
t test, ANCOVA and the chi-square test. A P value
<0.05 was considered significant.
Results
Patient backgrounds
A total of 88 patients participated in the study. The final
disease stage was classified according to the 6th Union
for International Cancer Control (UICC) [18]. Twenty-
nine patients with EGC underwent ESD, and 59 under-
went a radical operation. The median age in the ESD
group [65.3 ± 7.5 years (46–83 years)] was significantly
older than that in the radical operation group [45.8 ±
6.7 years (24–80 years)]. There were 14 women in the
ESD group and 21 women in the radical operation
group. The location and gross tumour type were not sig-
nificantly different between the two groups. Although
the median size of the lesion was 2.7 ± 1.9 cm in the
ESD group and 3.5 ± 1.6 cm in the radical operation
group, there was no significant difference between the
two groups (Tables 1 and 2). Adjuvant chemotherapy
was not administered to any of the patients.
Table 1 The tumour characteristics of the patients in the ESD
and radical operation groups
ESD group Radical operation group P
n 29 59
Location of the tumour (%)
Posterior wall 6 (20.7) 11 (18.6) NS
Anterior wall 7 (24.1) 19 (32.2) NS
Lesser curvature 9 (31.1) 16 (27.1) NS
Greater curvature 7 (24.1) 13 (22) NS
Gross type of the tumour (%)
Superficial depressed type 17 (58.6) 33 (55.9) NS
Superficial elevated type 12 (41.4) 26 (44.1) NS
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Clinicopathological features of the tumours
There were no significant differences between the
tumour location and the gross tumour type in the ESD
and radical operation groups (Table 3).
Comparison of the clinical outcomes between the groups
The median length of the operation was significantly
longer for the patients who underwent a radical oper-
ation [78 ± 11.4 (65–133) min] compared with ESD
[53 ± 7.9 (30–110) min; P < 0.05]. The patients treated
by radical surgery had a longer median hospital stay
[21.7 ± 9.3 (11–55) days] compared with those who
underwent ESD [14.3 ± 3.7 (10–23) days; P < 0.05].
The median size of the lesions was not significantly
different between the two groups (2.7 ± 1.9 vs. 3.5 ±
1.6 cm). There was no perioperative mortality in ei-
ther group, but the overall complication rate was sig-
nificantly higher in the radical operation group
(Table 2). There was also a significant difference in
the depth of invasion between the two groups. The
rate of EGC with submucosal invasion was signifi-
cantly higher in the radical operation group than in
the ESD group (P < 0.05). The oncological clearance
was not significantly different between the two groups
(93.1 vs. 100 %, P > 0.05). In the ESD group, cancer
cells were detected at the margin of the resected
lesion in one patient whose pathological type was
signet-ring cell carcinoma; adenocarcinoma with an
intravascular tumour embolus and a low level of dif-
ferentiation was detected at the deep margin of the
resected lesion in another patient. These two patients
underwent another surgical procedure. The incidence
of complications in the radical operation group (9/59,
15.3 %) was higher than that in the ESD group
(6.9 %, 2/29). In the ESD group, post-ESD delayed
haemorrhage and abdominal pain were the major
complications. Post-ESD delayed haemorrhage oc-
curred (at 6 and 24 h after ESD) in two patients who
presented with hematemesis or/and haematochezia,
and both were effectively treated by emergency endo-
scopic haemostasis. The majority of patients had dif-
ferent degrees of abdominal pain that were relieved
after 24–48 h by symptomatic treatment. In the rad-
ical operation group, nine patients had complications,
including one patient with acute postoperative adhe-
sive ileus, three patients with symptomatic postopera-
tive residual gastritis, one patient with postoperative
hypoproteinaemia and seroperitoneum, one patient
with postoperative iron deficiency anaemia, two pa-
tients with marginal ulcers and one patient with post-
operative gastrointestinal disturbance. The patient
with acute postoperative adhesive ileus recovered well
after re-operation. The other complications were im-
proved or cured by conservative treatment, such as
medical treatment, nutritional support therapy or
symptomatic treatment (Tables 2 and 4).
Follow-up in the ESD and radical operation groups
Gastroscopy and observation (using the EORTC QLQ-
C30 questionnaire and EORTC QLQ-STO22 question-
naire) were performed at 1, 3, 6, 12, and 24 months
post-EDS. All patients completed the follow-up observa-
tion. There were no significant differences in the median
follow-up period between the ESD [26.9 ± 8.5 months
Table 2 The characteristics and clinical data of the patients in the ESD and radical operation groups
ESD group (tumour size,
0.8–5.0 cm)
Radical operation group
(tumour size, 1.1–5.7 cm)
P
N 29 59
Mean age (years) 65.3 ± 7.5 45.8 ± 6.7 <0.05
Mean size of the lesion (cm) 2.7 ± 1.9 3.5 ± 1.6 NS
Frequency of underlying cardiopulmonary disease (%) 17.2 5.1 <0.01
Frequency of anticoagulant therapy (%) 13.8 1.7 <0.01
Length of operation (min) 53 ± 7.9 78 ± 11.4 <0.05
Depth of invasion (mucosa: submucosa:muscularis propria) 27:02:00 47:12:00 <0.05
Hospitalisation (d) 14.3 ± 3.7 21.7 ± 9.3 <0.05
Oncological clearance (%) 93.1 100 NS
Incidence of complications (%) 6.9 15.3 <0.05
Table 3 The pathological type of the patients in the ESD and
radical operation groups




17 (58.6) 28 (47.5) NS
Moderately differentiated
adenocarcinoma
9 (31) 19 (32.2) NS
Minimally differentiated
adenocarcinoma
2 (6.9) 7 (11.9) NS
Signet ring cell carcinoma 1 (3.4) 5 (8.5) NS
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(1–5 years)] and radical operation [22.3 ± 9.4 months
(1–3.7 years)] groups. Regular gastroscopy confirmed
that the tumours did not recur in either of the groups
(Table 2).
Comparison of the QOL between ESD and radical
operation
The overall health status based on the EORTC QLQ-
C30 was significantly lower in the radical operation
group than in the ESD group (P < 0.05). When the 15
functional scales were compared, the physical function
and social function categories were significantly lower in
the radical operation group (P < 0.05); although the role,
emotional and cognitive function categories were also
lower in the radical operation group than in the ESD
group, the differences between the two groups were not
significant. In the nine categories pertaining to symptom
scales, the only symptoms that reached statistical sig-
nificance were fatigue (P < 0.05), nausea and vomiting
(P < 0.05), and loss of appetite and constipation (P < 0.05),
with the symptoms being significantly more common in
the radical operation group. The QOL based on all nine
categories of the QLQ-STO22 was lower in the radical op-
eration group, but the results were significantly different
for only three categories: reflux (P < 0.01), eating restric-
tions (P < 0.05) and body image (P < 0.05) (Table 5).
Discussion
The therapeutic methods used for EGC can be divided
into three categories: endoscopic therapy, laparoscopic-
assisted radical resection and standard radical gastrec-
tomy. Anastomotic fistula formation is the most com-
mon and serious complication of a radical operation and
is one of the main causes of death during the periopera-
tive period. The incidence of anastomotic fistula is
3~6.6 % [19, 20]. Pulmonary infections, pleural effusion,
incision infections, abdominal infections, subphrenic in-
fections and gastric paralysis syndrome are also common
complications [21–23]. Intraperitoneal haemorrhage,
acute myocardial infarction, duodenal stump fistula, gas-
tric dumping syndrome, bile reflux gastritis, anastomotic
bleeding, gastric retention, adhesive ileus and anasto-
motic stenosis are also perioperative and postoperative
complications [21–23]. Patients have occasionally died
because of postoperative complications. Gastric stump
cancer (GSC), iron deficiency anaemia and malnutrition
are the most common long-term complications. The in-
cidence of complications for a radical operation for EGC
is significantly reduced compared with those for ad-
vanced gastric cancer. The 5-year survival rate can be
higher than 90 %, especially for intramucosal invasive
EGC, which has a 5-year survival rate close to 100 %
[24]. A multicentre study with a large sample size re-
ported by Kitano et al. [25] (1294 patients who under-
went laparoscopic radical resection of EGC at 16
centres, with a median follow-up of 36 months) indi-
cated that the 5-year tumour-free survival rates after a
radical operation for stage Ia and Ib gastric cancer
(UICC classification) were 99.8 and 98.7 %, respectively
[18]. However, some patients developed different degrees
of physiological and nutritional disorders after subtotal
gastrectomy, such as iron-deficiency anaemia and mal-
nutrition. Because these can also lead to numerous
health problems and a decline in the QOL, they are
problems that cannot be ignored.
ESD was first used by Gotoda in 1999 and has been
one of the principal methods used for the treatment of
EGC and precancerous lesions [26]. It has the advan-
tages of providing a wider local excision, the possibility
of obtaining en-bloc specimens with free lateral margins,
maintaining the normal physiological structure and
allowing an accurate determination of the depth of
tumour invasion. A study of ESD for the treatment of
early disease at Changhai Hospital in Shanghai indicated
that the complete resection rate was 95.2 % and the
complete histological clearance rate was 90.2 %. These
findings suggest that ESD has similar efficacy to and
many advantages over radical surgery because ESD can
maintain the normal physiological structure [27, 28].
Bleeding and perforation are the major perioperative
complications of ESD [29]. Bleeding is the most com-
mon complication, and it frequently occurs in the intra-
operative period or during the first 24 h postoperatively.
A multicentre study by Goto et al. [30] reported that
postoperative haemorrhage occurred in 100 (5.5 %, 62
cases during the first 24 h postoperatively) of their 1184
patients who received ESD gastric mucosal tumours.
The incidence of perforations has been reported to range
from 3.5 to 6.1 % during ESD. Perforations are divided
into macro- and micro-perforations [31]. Micro-
perforations are the most common type [31]. Because
surgeons can immediately observe and successfully close
a perforation with endoclips, these perforations can




Postoperative delayed haemorrhage 2
Perforation
Acute postoperative adhesive ileus 1
Symptomatic postoperative residual gastritis 3
Postoperative hypoproteinaemia and seroperitoneum 1
Postoperative iron deficiency anaemia 1
Marginal ulcer 2
Postoperative gastrointestinal disturbance 1
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generally be treated conservatively without the need for
emergency surgery [31]. Ono [32] reported that the per-
foration rate was 3.9–5 %, with postoperative bleeding
noted in 7.8–8.7 % of patients in a study of 602 EGC pa-
tients undergoing ESD using an insulated-type diather-
mic knife (IT-ESD), but all were successfully treated
using an entirely endoscopic approach without the need
for gastrectomy. Luminal stenosis is the main long-term
complication of ESD, and endoscopic dilation is an effi-
cacious and safe treatment for this condition [33, 34].
The five-year survival rates for the EGC patients treated
by ESD was 96.2–100.0 %, whilst the loco-regional re-
currence and distant metastasis rates were approxi-
mately 0–17.5 % and were similar to those following
radical surgery [35].
The oncological clearance in the present patients in the
ESD group was 93.1 % (27/29). Postoperative delayed
haemorrhage occurred in two patients. The postoperative
QOL was better, and the daily life and the normal
work of patients were not significantly affected in this
group. In the radical operation group, the oncological
clearance was 100 % (59/59). Nine patients had com-
plications, but the symptoms in most patients were
markedly improved after multimodality therapy, and
very few patients needed reoperation. Some prolonged
or recurrent complications, such as postoperative
ileus, symptomatic residual gastritis, marginal ulcers
and iron deficiency anaemia affected the nutritional
status of the patients and negatively impacted their
QOL. The EORTC QLQ-STO22 and EORTC QLQ-
STO30 also confirmed that the QOL in the radical
operation group was significantly lower than that in
the ESD group. This is one of the advantages of ESD
compared with radical surgery. Gastric stump cancer
has not been observed in any of the patients treated
by radical surgery. There have also been no cases of
Table 5 The quality of life of the patients in the ESD and radical operation groups
ESD group (n = 29) Radical operation group (n = 59) P
QLQ-C30 function
Overall health status 86.8 ± 23.4 76.5 ± 18.6 <0.05
Physical functioning 79.2 ± 16.3 70.5 ± 14.1 <0.05
Role functioning 88.4 ± 25.3 79.8 ± 27.7 NS
Emotional functioning 82.3 ± 18.2 77.5 ± 17.6 NS
Cognitive functioning 87.4 ± 16.2 83.7 ± 15.3 NS
Social functioning 84.9 ± 15.3 72.5 ± 26.8 <0.05
QLQ-C30 symptoms
Fatigue 15.3 ± 6.5 24.8 ± 11.3 <0.05
Nausea and vomiting 9.6 ± 5.6 17.3 ± 7.8 <0.05
Pain 8.1 ± 3.3 10.8 ± 6.9 NS
Dyspnoea 3.8 ± 2.3 5.5 ± 3.2 NS
Insomnia 9.1 ± 7.5 14.3 ± 5.8 NS
Loss of appetite 7.3 ± 4.2 15.6 ± 8.8 <0.05
Constipation 6.8 ± 5.5 16.2 ± 9.4 <0.05
Diarrhoea 8.5 ± 5.9 11.3 ± 6.3 NS
Financial difficulties 9.9 ± 3.4 13.3 ± 6.5 NS
QLQ-STO22 symptoms
Dysphagia 10.3 ± 8.7 15.7 ± 7.9 NS
Pain 9.6 ± 5.1 15.3 ± 9.4 NS
Reflux 8.0 ± 8.6 21.5 ± 6.8 <0.01
Eating restrictions 6.7 ± 5.9 13.6 ± 11.8 <0.05
Anxiety 11.9 ± 5.5 18.9 ± 7.1 NS
Dry mouth 11.5 ± 8.9 16.6 ± 6.3 NS
Taste problems 10.3 ± 8.3 14.5 ± 8.9 NS
Body image issues 12.5 ± 5.1 21.4 ± 5.5 <0.05
Hair loss 9.6 ± 3.2 11.6 ± 3.5 NS
P were calculated by ANCOVA adjusted for gender and follow up duration
QLQ quality of life questionnaire
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loco-regional recurrence or distant metastasis
amongst the patients treated by ESD or radical sur-
gery during the follow-up period.
These findings indicate that ESD achieved similar effi-
cacy and was advantageous compared with radical sur-
gery for the treatment of EGC [36]. Nevertheless, only a
small number of patients were included in this study,
and the median follow-up was not sufficient to evaluate
the long-term recurrence rate. Furthermore, it was a
retrospective study that may have led to some bias. Al-
though it is theoretically feasible for the patients with
EGC to be randomly divided into two groups for ESD or
a radical operation, this would not conform to the prin-
ciples of medical ethics. Along with the ever-increasing
use of ESD for EGC and the continuous extension of the
follow-up period, we will try to obtain extended follow-
up data of more than 15 years in order to evaluate the
long-term prognosis of EGC patients treated by ESD
and radical surgery. We expect that the results of the
present study will be confirmed by prospective rando-
mised analyses and that such studies would provide a
more objective evaluation.
Conclusions
This study indicates that ESD can achieve similar effi-
cacy compared with radical surgery for the treatment of
EGC with appropriate case selection. The patients
treated by ESD had better outcomes, including a shorter
operation, lower incidence of complications, shorter hos-
pital stay, similar oncological clearance and a better
QOL than those treated by radical surgery.
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